@inbook{MTMT:3134694,
	title = {Protective Effects of PACAP in the Retina},
	url = {https://m2.mtmt.hu/api/publication/3134694},
	author = {Atlasz, Tamás and Váczy, Alexandra and Werling, Dóra and Kiss, Péter and Tamás, Andrea and Kovács, Krisztina and Fábián, Eszter and Kvárik, Tímea and Mammel, Barbara and Dányádi, Bese and Lőkös, Emese and Reglődi, Dóra},
	booktitle = {Pituitary Adenylate Cyclase Activating Polypeptide — PACAP},
	doi = {10.1007/978-3-319-35135-3_30},
	unique-id = {3134694},
	year = {2016},
	pages = {501-527},
	orcid-numbers = {Atlasz, Tamás/0000-0002-8112-8633}
}

@article{MTMT:3127952,
	title = {Ocular delivery of PACAP1-27 protects the retina from ischemic damage in rodents},
	url = {https://m2.mtmt.hu/api/publication/3127952},
	author = {Werling, Dóra and Reglődi, Dóra and Banks, William A and Salameh, Theresa S and Kovács, Krisztina and Kvárik, Tímea and Váczy, Alexandra and Kovács, László Ákos and Mayer, Flora and Dányádi, Bese and Lőkös, Emese and Tamás, Andrea and Tóth, Gábor and Biró, Zsolt and Atlasz, Tamás},
	doi = {10.1167/iovs.16-20630},
	journal-iso = {INVEST OPHTH VIS SCI},
	journal = {INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE},
	volume = {57},
	unique-id = {3127952},
	issn = {0146-0404},
	abstract = {Purpose: Pituitary adenylate cyclase activating polypeptide (PACAP) is neuroprotective in neuronal injuries. Bilateral common carotid artery occlusion (BCCAO) causes chronic hypoperfusion-induced degeneration in the rat retina, where we proved the retinoprotective effect of intravitreal PACAP. Although this route of administration is a common clinical practice in several diseases, easier routes are clinically important. Our aim was to investigate the potential retinoprotective effects of PACAP eye drops in BCCAO-induced ischemic retinopathy.
		
		Methods: After performing BCCAO in rats, the right eyes were treated with PACAP1-27 eye drops (1 μg/drop, 2 × 1 drops/day for 5 days), containing different vehicles: saline, water for injections, thiomersal or benzalkonium solution for ophthalmic use (SOCB). Histology and immunohistochemistry were performed 2 weeks after surgery, while molecular analysis was performed 24 hours after BCCAO. Passage of PACAP1-27 through the ocular layers was tested with radioactive PACAP-SOCB in mice.
		
		Results: Bilateral common carotid artery occlusion led to a severe degeneration of all retinal layers. Solution for ophthalmic use was the most effective vehicle for delivering PACAP (PACAP-SOCB), significantly ameliorating BCCAO-induced damage. The massive upregulation of GFAP was not observed in retinas treated with PACAP-SOCB eye drops. PACAP-SOCB treatment also increased activation of the protective Akt and ERK1/2 in hypoperfused retinas. The cytokine profile showing upregulation in different cytokines was attenuated by PACAP-SOCB. Radioactive PACAP reached the retina when delivered in SOCB-containing eye drops.
		
		Conclusions: PACAP1-27, delivered in the SOCB vehicle as eye drops, was retinoprotective in ischemic retinopathy, providing the basis for future therapeutic administration.},
	year = {2016},
	eissn = {1552-5783},
	pages = {6683-6691},
	orcid-numbers = {Tóth, Gábor/0000-0002-3604-4385; Atlasz, Tamás/0000-0002-8112-8633}
}

@article{MTMT:3105000,
	title = {The Protective Role of PAC1-Receptor Agonist Maxadilan in BCCAO-Induced Retinal Degeneration},
	url = {https://m2.mtmt.hu/api/publication/3105000},
	author = {Váczy, Alexandra and Reglődi, Dóra and Somoskeoy, T and Kovács, Krisztina and Lőkös, Emese and Szabó, Edina and Tamás, Andrea and Atlasz, Tamás},
	doi = {10.1007/s12031-016-0818-4},
	journal-iso = {J MOL NEUROSCI},
	journal = {JOURNAL OF MOLECULAR NEUROSCIENCE},
	volume = {60},
	unique-id = {3105000},
	issn = {0895-8696},
	abstract = {A number of studies have proven that pituitary adenylate cyclase activating polypeptide (PACAP) is protective in neurodegenerative diseases. Permanent bilateral common carotid artery occlusion (BCCAO) causes severe degeneration in the rat retina. In our previous studies, protective effects were observed with PACAP1-38, PACAP1-27, and VIP but not with their related peptides, glucagon, or secretin in BCCAO. All three PACAP receptors (PAC1, VPAC1, VPAC2) appear in the retina. Molecular and immunohistochemical analysis demonstrated that the retinoprotective effects are most probably mainly mediated by the PAC1 receptor. The aim of the present study was to investigate the retinoprotective effects of a selective PAC1-receptor agonist maxadilan in BCCAO-induced retinopathy. Wistar rats were used in the experiment. After performing BCCAO, the right eye was treated with intravitreal maxadilan (0.1 or 1 muM), while the left eye was injected with vehicle. Sham-operated rats received the same treatment. Two weeks after the operation, retinas were processed for standard morphometric and molecular analysis. Intravitreal injection of 0.1 or 1 muM maxadilan caused significant protection in the thickness of most retinal layers and the number of cells in the GCL compared to the BCCAO-operated eyes. In addition, 1 muM maxadilan application was more effective than 0.1 muM maxadilan treatment in the ONL, INL, IPL, and the entire retina (OLM-ILM). Maxadilan treatment significantly decreased cytokine expression (CINC-1, IL-1alpha, and L-selectin) in ischemia. In summary, our histological and molecular analysis showed that maxadilan, a selective PAC1 receptor agonist, has a protective role in BCCAO-induced retinal degeneration, further supporting the role of PAC1 receptor conveying the retinoprotective effects of PACAP.},
	year = {2016},
	eissn = {1559-1166},
	pages = {186-194},
	orcid-numbers = {Atlasz, Tamás/0000-0002-8112-8633}
}